Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × palbociclib × Genitourinary × Clear all

Phase

Phase 2 9 Phase 1 3 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 32 Sarcoma 1 Genitourinary 1

Conditions

von Hippel-Lindau Disease 1 Carcinoma, Renal Cell 1

Interventions

Docetaxel 77 Radiotherapy 74 Prednisone 65 Leuprolide 51 Goserelin 49 Gemcitabine 48 Cisplatin 47 bicalutamide 46 enzalutamide 41 Androgen Antagonists 35 pembrolizumab 31 Abiraterone Acetate 30 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28 Mitomycin 28 Magnetic Resonance Spectroscopy 28 Carboplatin 27 Flutamide 25 Triptorelin Pamoate 23 Sunitinib 23 Nivolumab 23 Radiation 22 apalutamide 21 Doxorubicin 20 darolutamide 18 Gonadotropin-Releasing Hormone 17 cabozantinib 16 abiraterone 16 Specimen Handling 16 Paclitaxel 16 atezolizumab 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07405164 2026-04-17

MK-6482-043

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡